İçeriğe Atlayın Skip to Content
TREN

Articles by Cancer Type

What the treatment decision rests on in breast, lung, pancreatic and other cancers. Subtypes, biomarkers and randomised trial results explained in plain language.

Articles Under This Heading

Illustration of tumour cells within a breast ductCancer Types

How the Treatment Decision Is Made in Hormone Receptor-Positive Breast Cancer

Is chemotherapy needed in hormone receptor-positive breast cancer, what do genomic assays decide, and how long does endocrine therapy last?

Read the Article
Diagram of the genes covered by biomarker testing in lung cancerCancer Types

When Is Biomarker Testing in Lung Cancer Requested?

Which genes biomarker testing in lung cancer covers, when it is requested, and whether tissue or blood should be used. Guideline-based answers.

Read the Article
Chart of the variants of KRAS in pancreatic cancer and how often each occursCancer Types

KRAS in Pancreatic Cancer and the New Treatments

Why KRAS in pancreatic cancer is so common, what the variants change, and where the new drugs stand. The role of genomic profiling explained.

Read the Article
Microscopic examination of a pathology sample in cancer of unknown primaryCancer Types

How Is Cancer of Unknown Primary Diagnosed?

How cancer of unknown primary is diagnosed, which tests are used and what molecular profiling changes, with the randomised evidence.

Read the Article
Table comparing trastuzumab deruxtecan with T-DM1 in the DESTINY-Breast05 trialCancer Types

What Trastuzumab Deruxtecan Changed in Early Breast Cancer

Trastuzumab deruxtecan has replaced T-DM1 when tumour remains after treatment given before surgery. The DESTINY-Breast05 results and the lung risk.

Read the Article
Table of the results of adding immunotherapy in stomach cancer in the MATTERHORN trialCancer Types

Immunotherapy in Stomach Cancer Has Moved to the Time Around Surgery

Immunotherapy in stomach cancer is no longer confined to metastatic disease. MATTERHORN measured what adding durvalumab to the FLOT regimen achieves.

Read the Article
Table of survival outcomes in ctDNA-positive and ctDNA-negative patients after surgery for muscle-invasive bladder cancerCancer Types

What ctDNA Changes in Muscle-Invasive Bladder Cancer

In muscle-invasive bladder cancer, atezolizumab extended disease-free and overall survival in patients who turned ctDNA-positive after surgery.

Read the Article

Other Headings: Diagnosis and Treatment · Genetic and Molecular Oncology · Life and Support · Oncology News · All Articles

Ask for an Assessment

You can send your pathology and imaging reports on WhatsApp or by email. Documents are reviewed before the consultation.